

HPTN Studies	2025				2026				2027				2028				2029				2030			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Novel ARV Methods																								
HPTN 083 (CAB LA OLE)																								
HPTN 084 (CAB LA Pregnancy)												- 2	- 3	- 3	- 3		0.00		0		3	- 3	3	
HPTN 102 (LEN in Women)																								
HPTN 103 (LEN in PWID)																	90 0	- 8	0.00		- 8	- 8	- 8	
HPTN 106 (Rectal Douche)																								,
MPTs																								
HPTN 104 (DPP)													- "				S							
bnAbs															j									
HVTN 805/HPTN 093 (ATI in Africa)																								
HVTN 804/HPTN 095 (ATI in Americas)									3	- 3	- 8	98	- 8	- 6	- 8	- 8	90 0	- 8	90 0		0	- 8	- 3	
HVTN 141/HPTN 105 (Triple mAb)													-											
A5416/HVTN 806/HPTN 108 (ATI in RSA)															- 8	. 88	90 0	- 8	0.00		- 8	- 8	- 3	
HVTN 206/HPTN 114 (mAb Combo)																								,
Integrated Strategies																								
HPTN 091 (Gender-affirming care and PrEP)																	S.							
HPTN 094 (Mobile vans in PWID)				200	- 0				- 8		- 8	20	0.00	3	8	0.88	96 0	3	0.00		- 8	- 8	- 3	
HPTN 096 Post-Pilot (Interventions in Black MSM in the US)																								
HPTN 111 (Men in Ugandan Barbershops)								- 8	- 8	0.00	9	- 6	0.00	- 33	- 8		90 0	- 8	0.00		- 8	- 8	- 8	
HPTN 112 (Systems Navigators at STI Clinic w/ Men on PrEP)																								
HPTN 113 (Latino MSM PrEP & DoxyPrEP)														30	3	0.88	90 0	- 3	0.00	- 8	- 8	- 8	- 3	
HPTN 115/ATN 173 (Doxy PEP for US Adolescents)																								,
DMID 24-0020/HPTN 116 (Neurosyphilis Study)																								
HPTN 117 (PK and adherence of Doxycycline)									Ĭ		Ĭ		Ĭ	Î	Ĭ		Ĭ		Ĭ					
HPTN 118 (Adolescent 3E)		TE	BD.	1		18		- 8	- 2	8	- 8	- 3	- 8		- 3	- 3	- 8	- 3	- 8		- 8	- 3	- 8	- 0
HPTN 119 (DoxyPEP Africa)		TE	3D	Î															Ĭ					-

Pre-implementation

Implementation

Post-implementation -To publication of primary end point